Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Immunoglobulins
- Indications Transplant rejection
- Focus Therapeutic Use
- Acronyms TRIBUTE
- 08 Apr 2015 Planned End Date changed from 1 Apr 2018 to 1 Oct 2018, as reported by ClinicalTrials.gov.
- 08 Apr 2015 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018, as reported by ClinicalTrials.gov.
- 08 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.